Editorial standards

Scope

These standards apply to every drug monograph, condition overview, country-pathway explainer, and article on reservemeds.com. They do not apply to marketing collateral or investor materials.

Sourcing

Clinical claims are drawn from FDA-approved labeling, the European Medicines Agency product information, peer-reviewed primary literature, and recognized tertiary references (UpToDate, Lexicomp, Micromedex). Regulatory claims are drawn from the destination country's medicines authority — CDSCO (India), MOH/MOHAP (UAE), SFDA (Saudi Arabia), DRAP (Pakistan), MHRA (UK), and equivalent bodies. Pricing data is drawn from our internal sourcing records and published WAC references where available.

Review workflow

Every page is drafted against a standardized template, then reviewed in two passes. The first pass is clinical — our AI Pharmacist checks drug names, indications, dosing, interactions, and safety claims against current labeling. The second pass is regulatory — our AI Regulatory Counsel checks pathway language, country-specific claims, and compliance posture. A human pharmacist (licensed under Altima Care) reviews flagged items and signs off on the final version.

Transparency

Every page displays its last medical-review date and reviewer. Where AI tools are used in content production or review, that fact is disclosed on the page. We do not publish ghost-written sponsored content, and we do not accept payment to feature a drug or condition.

Corrections

If you identify a factual error, email [email protected]. We acknowledge within two business days, publish a corrected page within five, and preserve a visible note of the correction for 30 days before archiving it to our corrections log.

Update cadence

Drug monographs are reviewed at least every 180 days and within 30 days of a material FDA labeling change. Country-pathway pages are reviewed at least every 180 days and within 14 days of a regulatory bulletin from the relevant authority. Articles are reviewed annually or when cited data becomes stale.

What we will not publish

We do not publish off-label dosing recommendations, head-to-head efficacy claims not supported by controlled trials, testimonials attributed to unnamed patients, or pricing that differs from what we would actually charge. We do not publish anything that could reasonably be read as medical advice for a specific patient — that is what the treating physician is for.

Reviewed 2026-04-22 by Reserve Meds's AI Pharmacist and AI Regulatory Counsel. Next scheduled review: 2026-10-22.